Pharmaceuticals

HAIXI PHARMA

Northeast Securities Reiterates Buy Rating and Target Price for Fujian Haixi New Drug

Guohai Securities Reiterates Buy Rating for Fujian Haixi New Drug with Target Price

Fujian HxNew Drug Announces Annual Report and Clinical Trials Progress

Hai Xi New Drug Announces 2025 Profit Growth, Benefits from Marketing and VBP Selection

HAIXI PHARMA released FY2025 Annual Earnings on March 30, 2026 (BJT), with actual revenue of HKD 636.49 M and actual EPS of HKD 2.7836

Haisi New Drug Initiates Phase II Clinical Trials for HXP056

HAIXI PHARMA to Release FY2025 Earnings on March 30, 2026 (BJT)

HAIXI PHARMA released FY2023 Annual Earnings on October 8, 2025 (BJT) with actual revenue of HKD 347.71 M and EPS of HKD 1.9191

HAIXI PHARMA released FY2022 Annual Earnings on October 8, 2025 (BJT), with actual revenue of HKD 245.78 M and EPS of HKD 1.2416

HAIXI PHARMA released FY2024 Semi-Annual earnings on October 8, 2025 (BJT), actual revenue HKD 195.82 M, actual EPS HKD 1.0158

HAIXI PHARMA released FY2025 Semi-Annual earnings on October 8, 2025 (BJT) with actual revenue of HKD 268.77 M and EPS of HKD 1.4475

HAIXI PHARMA released FY2024 Annual Earnings on October 8, 2025 (BJT), actual revenue HKD 505.17 M, actual EPS HKD 2.1917

CH DEMETER FIN

FAMEGLOW

LUEN THAI

NEW GONOW RV

REF HOLDINGS

PARADISE ENT

WEBX HOLDING

HAICHANG HLDG

BEST FOOD HLDG

INTELLIMARK W27

02637

Northeast Securities has reaffirmed a Buy rating on Fujian Haixi Pharmaceuticals Co., Ltd. Class H (2637) as of May 8, setting a price target of HK$346.75. The stock closed at HK$236.00 last Friday. The analyst consensus for the company is Strong Buy, with a price target consensus of HK$320.72.

Tip Ranks

Northeast Securities

Northeast Securities Reaffirms Their Buy Rating on Fujian Haixi Pharmaceuticals Co., Ltd. Class H (2637)

Guohai Securities has reaffirmed its Buy rating for Fujian Haixi Pharmaceuticals Co., Ltd. Class H (2637), setting a price target of HK$339.55. The stock closed at HK$258.00. The overall analyst consensus for the company is a Strong Buy, with an average price target of HK$312.04.

Sealand Securities

Guohai Securities Sticks to Its Buy Rating for Fujian Haixi Pharmaceuticals Co., Ltd. Class H (2637)

09903

02427

09636

06082

06600

00981

02940

00004

01516

ILUVATAR COREX(09903) rose 21.3%, with a trading turnover 1.1 Billion HKD, and a year-to-date rose 222.1%. GUANZE MEDICAL(02427) rose 12.41%, with a trading turnover 21.9 Million HKD, and a year-to-date rose 1335.8%. HAIXI PHARMA(02637) rose 9.21%, with a trading turnover 300.5 Million HKD, and a year-to-date rose 91.9%.

Top Gainers&Losers

ILUVATAR COREX

GUANZE MEDICAL

JF SMARTINVEST

BIREN TECH

ONEROBOTICS

SMIC

WELLCELL HOLD

WHARF HOLDINGS

SUNAC SERVICES

Top 10 HK Stock Gainers (4.30)

HAIXI PHARMA rose by 13.47%; CSPC Pharmaceutical Group fell by 0.60%, with a transaction volume of HKD 488 million; China Biologic Products fell by 0.92%, with a transaction volume of HKD 156 million; Hansoh Pharmaceutical rose by 0.27%, with a transaction volume of HKD 153 million; Heng Rui Medicine fell by 2.10%, with a market value of HKD 432.4 billion

HK Stock Alerts

CSPC PHARMA

SBP GROUP

HANSOH PHARMA

HENGRUI PHARMA

Hong Kong stock movement: HAIXI PHARMA's stock price fluctuates sharply, can the incentive plan and profit expectations stabilize market confidence?

02656

01361

02650

06166

03317

00679

02513

01057

02315

160 HEALTH(02656) fell 22.67%, with a trading turnover 671.5 Million HKD, and a year-to-date fell 60.5%. HAIXI PHARMA(02637) fell 21.01%, with a trading turnover 418.0 Million HKD, and a year-to-date rose 63.1%. 361 DEGREES(01361) fell 20.52%, with a trading turnover 978.7 Million HKD, and a year-to-date fell 9.2%.

160 HEALTH

361 DEGREES

ZHIDA TECH

XUNCE

ASIA TELE-NET

KNOWLEDGE ATLAS

ZHEJIANG SHIBAO

BIOCYTOGEN-B

Top 10 HK Stock Losers (4.28)

HAIXI PHARMA fell 16.03%; CSPC Pharmaceutical Group fell 4.09%, with a transaction volume of HKD 542 million; China Biologic Products fell 2.53%, with a transaction volume of HKD 293 million; Kelun Pharmaceutical rose 7.43%, with a transaction volume of HKD 231 million; Heng Rui Medicine fell 0.67%, with a market value of HKD 445.7 billion

Hong Kong Stock Movement: HAIXI PHARMA falls 16.03%, analysts maintain buy rating but struggle to restore market confidence

HAIXI PHARMA fell 16.52%; CSPC Pharmaceutical Group fell 1.14%, with a transaction volume of HKD 255 million; China Biologic Products fell 0.90%, with a transaction volume of HKD 174 million; Kelun Pharmaceutical rose 6.95%, with a transaction volume of HKD 136 million; Heng Rui Medicine rose 0.30%, with a market value of HKD 450 billion

Hong Kong stock movement: HAIXI PHARMA fell 16.52%, can the analyst target price of HKD 298.28 reverse the decline?

HAIXI PHARMA fell 11.89%; CSPC Pharmaceutical Group fell 0.91%, with a transaction volume of HKD 221 million; China Biologic Products fell 0.72%, with a transaction volume of HKD 167 million; Kelun Pharmaceutical rose 7.62%, with a transaction volume of HKD 128 million; Heng Rui Medicine rose 1.11%, with a market value of HKD 453.7 billion

Hong Kong stock movement: HAIXI PHARMA fell 11.89%, analysts maintain buy rating but struggle to restore market confidence

HAIXI PHARMA(02637.HK)